October 2024

CARDIOVASCULAR

SANJIV J. SHAH, MD: THE IMPACT OF THE MAGNITUDE TRIAL

Featuring: Sanjiv J. Shah, MD​

Episode Summary

Sanjiv J. Shah, MD elaborates on the objectives and significance of the MAGNITUDE clinical trial, the first large-scale phase 3 trial for gene-editing therapy. Dr. Shah is the principal investigator for the trial at Northwestern Medicine’s site.

​To refer a patient, please call the Clinical Trials Unit at Northwestern Medicine Bluhm Cardiovascular Institute: 312.926.400.
Sanjiv J. Shah, MD, Director of the Institute for Artificial Intelligence in Medicine - Center for Deep Phenotyping and Precision Therapeutics, Neil J. Stone, MD, Professor, and Professor, of Cardiology

Refer a Patient

Northwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients. ​

You May Also Like